BioCentury | Apr 2, 2021
Management Tracks

BeiGene unveils new CFO; plus Precigen, Alphamab, Flagship, Melinta, Immunome and more

...replacing Giuseppe Del Priore. Tornout has led clinical management and oncology teams at Natera Inc. (NASDAQ:NTRA), Inovio Pharmaceuticals Inc....
BioCentury | Mar 27, 2021
Product Development

What it will take to meet CEPI’s 100-day vaccine goal for the next pandemic

...T cell responses, as reported in the NEJM.Inovio Pharmaceuticals Inc....
BioCentury | Mar 12, 2021
Product Development

DNA lagging in the COVID-19 vaccine race: Data Byte

...NSE:CADILAHC; BSE:532321) has the most advanced DNA vaccine; ZyCoV-D is in Phase III testing. The runner-up, INO-4800 from Inovio Pharmaceuticals Inc....
...programs, hit a delay in September with a partial hold on its Phase II/III trial. Inovio...
BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

...Global Bio Fund with participation from all existing series A investors including Santé Ventures and Inovio Pharmaceuticals Inc....
BioCentury | Mar 2, 2021
Regulation

Novavax preps for Q2 COVID vaccine EUA submission; plus Fibrogen, Inovio, J&J, Aslan, Merck, Oncopeptides and Athenex

...PDUFA date for the therapy, which is approved in China, Chile and Japan, is March 20.Inovio...
...MK-3475, lambrolizumab) Evrenzo, roxadustat (ASP1517, FG-4592) NVX-CoV2373 Oncopeptides AB Merck & Co. Inc. Athenex Inc. FibroGen Inc. AstraZeneca plc Aslan Pharmaceuticals Ltd. Johnson & Johnson Inovio Pharmaceuticals Inc. Novavax...
BioCentury | Feb 5, 2021
Finance

GameStop survivors target biotech shares, but ‘BioWar’ unlikely despite bolus of short-friendly stocks

...Pharmaceuticals Inc. (NASDAQ:BCRX), Cassava Sciences Inc. (NASDAQ:SAVA) and Inovio Pharmaceuticals Inc....
...Inc. (NASDAQ:LGND), Clovis Oncology Inc. (NASDAQ:CLVS), Esperion Therapeutics Inc. (NASDAQ:ESPR), Inovio...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...moving, Vir among biotechs with high short interestA FactSet analysis named Ligand Pharmaceuticals Inc. (NASDAQ:LGND), Inovio Pharmaceuticals Inc....
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...Neuroscience R&D; and CBO Paul Stead, who held BD roles at GSK, Nimbus Therapeutics LLC, Inovio Pharmaceuticals Inc....
BioCentury | Jan 5, 2021
Product Development

COVID roundup: Emergency approval in India for Serum Institute, Bharat vaccines; plus Inovio-Advaccine and Moderna

...up to 96.3% at two weeks post-boost and mean neutralizing titers up to 160.1 in microneutralization assays.Inovio...
...to develop, manufacture and commercialize COVID-19 vaccine INO-4800 in China, Hong Kong, Macau and Taiwan. Inovio...
...pipeline “without the need for additional near-term capital raises.” Sandi Wong AZD1222 (ChAdOx1 nCoV-19) Bharat-COVID-19-unknown INO-4800 [MERGED] AstraZeneca plc University of Oxford Inovio Pharmaceuticals Inc. Moderna...
BioCentury | Dec 29, 2020
Product Development

Inovio COVID vaccine leans toward T cell responses: Data Byte

...By Sandi Wong, Assistant Editor Phase I data for Inovio’s COVID-19 vaccine suggest INO-4800 may stimulate T cell...
...shares fell $0.66 to $9.60. The tepid market reception suggests that, as in June when shares of Inovio Pharmaceuticals Inc....
...T cell responses can compensate for weak humoral immunity, indicating the T cell responses induced by Inovio’s...
Items per page:
1 - 10 of 297
BioCentury | Apr 2, 2021
Management Tracks

BeiGene unveils new CFO; plus Precigen, Alphamab, Flagship, Melinta, Immunome and more

...replacing Giuseppe Del Priore. Tornout has led clinical management and oncology teams at Natera Inc. (NASDAQ:NTRA), Inovio Pharmaceuticals Inc....
BioCentury | Mar 27, 2021
Product Development

What it will take to meet CEPI’s 100-day vaccine goal for the next pandemic

...T cell responses, as reported in the NEJM.Inovio Pharmaceuticals Inc....
BioCentury | Mar 12, 2021
Product Development

DNA lagging in the COVID-19 vaccine race: Data Byte

...NSE:CADILAHC; BSE:532321) has the most advanced DNA vaccine; ZyCoV-D is in Phase III testing. The runner-up, INO-4800 from Inovio Pharmaceuticals Inc....
...programs, hit a delay in September with a partial hold on its Phase II/III trial. Inovio...
BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

...Global Bio Fund with participation from all existing series A investors including Santé Ventures and Inovio Pharmaceuticals Inc....
BioCentury | Mar 2, 2021
Regulation

Novavax preps for Q2 COVID vaccine EUA submission; plus Fibrogen, Inovio, J&J, Aslan, Merck, Oncopeptides and Athenex

...PDUFA date for the therapy, which is approved in China, Chile and Japan, is March 20.Inovio...
...MK-3475, lambrolizumab) Evrenzo, roxadustat (ASP1517, FG-4592) NVX-CoV2373 Oncopeptides AB Merck & Co. Inc. Athenex Inc. FibroGen Inc. AstraZeneca plc Aslan Pharmaceuticals Ltd. Johnson & Johnson Inovio Pharmaceuticals Inc. Novavax...
BioCentury | Feb 5, 2021
Finance

GameStop survivors target biotech shares, but ‘BioWar’ unlikely despite bolus of short-friendly stocks

...Pharmaceuticals Inc. (NASDAQ:BCRX), Cassava Sciences Inc. (NASDAQ:SAVA) and Inovio Pharmaceuticals Inc....
...Inc. (NASDAQ:LGND), Clovis Oncology Inc. (NASDAQ:CLVS), Esperion Therapeutics Inc. (NASDAQ:ESPR), Inovio...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...moving, Vir among biotechs with high short interestA FactSet analysis named Ligand Pharmaceuticals Inc. (NASDAQ:LGND), Inovio Pharmaceuticals Inc....
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...Neuroscience R&D; and CBO Paul Stead, who held BD roles at GSK, Nimbus Therapeutics LLC, Inovio Pharmaceuticals Inc....
BioCentury | Jan 5, 2021
Product Development

COVID roundup: Emergency approval in India for Serum Institute, Bharat vaccines; plus Inovio-Advaccine and Moderna

...up to 96.3% at two weeks post-boost and mean neutralizing titers up to 160.1 in microneutralization assays.Inovio...
...to develop, manufacture and commercialize COVID-19 vaccine INO-4800 in China, Hong Kong, Macau and Taiwan. Inovio...
...pipeline “without the need for additional near-term capital raises.” Sandi Wong AZD1222 (ChAdOx1 nCoV-19) Bharat-COVID-19-unknown INO-4800 [MERGED] AstraZeneca plc University of Oxford Inovio Pharmaceuticals Inc. Moderna...
BioCentury | Dec 29, 2020
Product Development

Inovio COVID vaccine leans toward T cell responses: Data Byte

...By Sandi Wong, Assistant Editor Phase I data for Inovio’s COVID-19 vaccine suggest INO-4800 may stimulate T cell...
...shares fell $0.66 to $9.60. The tepid market reception suggests that, as in June when shares of Inovio Pharmaceuticals Inc....
...T cell responses can compensate for weak humoral immunity, indicating the T cell responses induced by Inovio’s...
Items per page:
1 - 10 of 297